强生新型疫苗9月进入首阶段临床测试 最快明年初推出
美国个人保健及药物企业强生(Johnson & Johnson)表示,新型冠状病毒疫苗人体测试会在9月展开,并会在紧急使用认证下,於明年初可推出市场。公司同时承诺投资额外10亿美元,投放於美国卫生及公共服务部旗下生物医药先进研发管理局的夥伴计划。
强生的疫苗测试将於9月进入首阶段人体临床测试,测试数据料於年底前取得。若疫苗有效,疫苗将於明年初作紧急使用。
受消息刺激,强生股价昨日(30日)升8%,为升幅最大道指成分股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.